Stefania Tacconelli

ORCID: 0000-0003-4907-1822
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Inflammatory mediators and NSAID effects
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Eicosanoids and Hypertension Pharmacology
  • Synthesis of β-Lactam Compounds
  • Pharmacogenetics and Drug Metabolism
  • Estrogen and related hormone effects
  • Venous Thromboembolism Diagnosis and Management
  • Cancer, Lipids, and Metabolism
  • Hormonal Regulation and Hypertension
  • Inflammatory Biomarkers in Disease Prognosis
  • Neuropeptides and Animal Physiology
  • Antioxidant Activity and Oxidative Stress
  • Analytical Methods in Pharmaceuticals
  • Helicobacter pylori-related gastroenterology studies
  • Cancer-related molecular mechanisms research
  • Lipoproteins and Cardiovascular Health
  • Blood Pressure and Hypertension Studies
  • Extracellular vesicles in disease
  • Free Radicals and Antioxidants
  • Platelet Disorders and Treatments
  • Drug-Induced Adverse Reactions
  • Peroxisome Proliferator-Activated Receptors
  • Alcohol Consumption and Health Effects
  • Adenosine and Purinergic Signaling
  • Gastroesophageal reflux and treatments

University of Chieti-Pescara
2015-2025

University of Pennsylvania
2006-2019

Translational Therapeutics (United States)
2006-2019

Shanghai Institutes for Biological Sciences
2019

Chinese Academy of Sciences
2019

Tianjin Medical University
2019

Catholic University of America
2000-2019

Institute on Aging
2012

Ospedale SS. Annunziata
2004-2011

New York Medical College
2008

The current controversy on the potential cardioprotective effect of naproxen prompted us to evaluate extent and duration platelet, monocyte, vascular cyclooxygenase (COX) inhibition by compared with low-dose aspirin.We performed a crossover, open-label study aspirin (100 mg/d) or (500 mg BID) administered 9 healthy subjects for 6 days. effects thromboxane (TX) prostacyclin biosynthesis were assessed up 24 hours after oral dosing. Serum TXB2, plasma prostaglandin (PG) E2, urinary...

10.1161/01.cir.0000124715.27937.78 article EN Circulation 2004-03-23

Hypertensive patients with renovascular disease (RVD) may be exposed to increased oxidative stress, possibly related activation of the renin-angiotensin system.We measured urinary excretion 8-iso-prostaglandin (PG) F2alpha and 11-dehydro-thromboxane (TX) B2 as indexes in vivo lipid peroxidation platelet activation, respectively, 25 RVD, essential hypertension, healthy subjects. Plasma renin activity peripheral renal veins, angiotensin II cholesterol, glucose, triglycerides, homocysteine,...

10.1161/01.cir.0000039528.49161.e9 article EN Circulation 2002-11-25

Diabetes mellitus is associated with platelet hyperactivity, which leads to increased morbidity and mortality from cardiovascular disease. This coupled enhanced levels of thromboxane (TX), an eicosanoid that facilitates aggregation. Although intensely studied, the mechanism underlying relationship among hyperglycemia, TX generation, hyperactivity remains unclear. We sought identify key signaling components connect high glucose generation examine their clinical relevance. In human platelets,...

10.1172/jci59291 article EN Journal of Clinical Investigation 2011-10-17

Aspirin affords cardioprotection through the acetylation of serine 529 in human cyclooxygenase-1 (COX-1) anucleated platelets, inducing a permanent defect thromboxane A 2 (TXA )–dependent platelet function. However, heterogeneity COX-1 suppression by aspirin has been detected cardiovascular disease and may contribute to failure prevent clinical events. The recent recognized capacity platelets make proteins de novo paves way identify new mechanisms involved variable response aspirin. We found...

10.1161/01.res.0000214553.37930.3e article EN Circulation Research 2006-02-17

We performed a placebo-controlled, randomized study to address whether celecoxib or ibuprofen undermines the functional range of inhibition platelet cyclooxygenase (COX)-1 activity by aspirin in patients with osteoarthritis and stable ischemic heart disease.Twenty-four who were undergoing long-term treatment (100 mg daily) for cardioprotection coadministered celecoxib, 200 twice daily, ibuprofen, 600 3 times placebo 7 days.The coadministration did not undermine aspirin-related COX-1...

10.1016/j.clpt.2006.05.004 article EN Clinical Pharmacology & Therapeutics 2006-09-01

3-(5-Chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6), a known selective cyclooxygenase-1 (COX-1) inhibitor, was used to design new series of 3,4-diarylisoxazoles in order improve its biochemical COX-1 selectivity and antiplatelet efficacy. Structure-activity relationships were studied using human whole blood assays for COX-2 inhibition vitro, results showed that the simultaneous presence 5-methyl (or -CF3), 4-phenyl, 5-chloro(-bromo or -methyl)furan-2-yl groups on isoxazole core essential...

10.1021/jm301905a article EN Journal of Medicinal Chemistry 2013-05-07

Recent findings have shown that aspirin, taken for several years, reduces the long-term risk of some cancers, particularly colorectal cancer. The result aspirin benefit is detectable at daily low-doses (at least 75mg), same used prevention cardiovascular disease, positions antiplatelet action center its antitumor efficacy. At given every 24 h, acting by a complete and persistent inhibition cyclooxygenase (COX)-1 in platelets (in pre-systemic circulation) while causing limited rapidly...

10.3390/ph5121346 article EN cc-by Pharmaceuticals 2012-12-05

Platelet-cancer cell interactions modulate tumor metastasis and thrombosis in cancer. Platelet-derived extracellular vesicles (EVs) can contribute to these outcomes.We characterized the medium-sized EVs (mEVs) released by thrombin-stimulated platelets of colorectal cancer (CRC) patients healthy subjects (HS) on capacity induce epithelial-mesenchymal transition (EMT)-related genes cyclooxygenase (COX)-2(PTGS2), thromboxane (TX)B2 production cocultures with four lines. mEVs were assessed for...

10.3390/cancers15020350 article EN Cancers 2023-01-05

Background —Increased formation of 8-iso-prostaglandin (PG) F 2α and thromboxane (TX) A 2 , potent agonists platelet vascular (TH)/PGH receptors, has been detected in cigarette smokers. We performed a randomized, double-blind, placebo-controlled study the effects vitamin E (300, 600, 1200 mg/d, each dose for 3 consecutive weeks) on 8-iso-PGF TXA biosynthesis 46 moderate Methods Results —Urinary immunoreactive 11-dehydro-TXB plasma E, serum TXB were measured by previously validated...

10.1161/01.cir.102.5.539 article EN Circulation 2000-08-01

The aim of the present cross-sectional study was to investigate whether activation renin-angiotensin system in renovascular disease affects cytochrome P450 omega/omega-1 hydroxylase (20-hydroxyeicosatetraenoic acid [20-HETE]) and epoxygenase (epoxyeicosatrienoic acids [EETs]) pathways arachidonic metabolism vivo, each which interacts with angiotensin II. Plasma concentration urinary excretion 20-HETE EETs their metabolites, dihydroxyeicosatrienoic acids, were measured urine plasma by mass...

10.1161/hypertensionaha.107.105395 article EN Hypertension 2008-04-01

We compared the variability in degree and recovery from steady-state inhibition of cyclooxygenase (COX)-1 COX-2 ex vivo platelet aggregation by naproxen sodium at 220 versus 440 mg b.i.d. low-dose aspirin healthy subjects. Six subjects received consecutively (220 b.i.d.) (100 daily) for 6 days, separated washout periods 2 weeks. COX-1 was determined using indices enzymatic activity: 1) measurement serum thromboxane (TX)B<sub>2</sub> levels whole-blood lipopolysaccharide-stimulated...

10.1124/jpet.107.122283 article EN Journal of Pharmacology and Experimental Therapeutics 2007-05-01

Background.Inflammation, oxidative damage, and platelet activation are hypothesized biological mechanisms driving the disablement process. The aim of present study is to assess whether biomarkers representing these predicted major adverse health-related events in older persons.

10.1093/gerona/glr246 article EN The Journals of Gerontology Series A 2012-03-01
Coming Soon ...